PROPHYSOME: Pilot Study on Safety of a Weekly Administration of 10mg/kg of AmBisome® in Antifungal Prophylaxis Treatment of Allogeneic Stem-cell Transplantation and Acute Leukaemia [clinicaltrials:NCT00362544]

Bio2RDF identifier

NCT00362544

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00362544

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00362544

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:f75c5a855582d3b6ab2bcdae185de445

brief summary [clinicaltrials_vocabulary:brief-summary]

This pilot study was de ...... ons development is concerned.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

PROPHYSOME: Pilot Study on Saf ...... plantation and Acute Leukaemia

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

The primary endpoint will be the safety defined by the incidence of adverse events occurring during the course of prophylaxis treatment (4 weeks for AL patients and 8 weeks for SCT patients). [clinicaltrials_resource:a1e25864ab72d77382ade854a3d99eb8]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

The primary endpoint will be the safety defined by the incidence of adverse events occurring during the course of prophylaxis treatment (4 weeks for AL patients and 8 weeks for SCT patients). [clinicaltrials_resource:2032cd90a4091027d922b1a849b8dea1]

The primary endpoint will be the safety defined by the incidence of adverse events occurring during the course of prophylaxis treatment (4 weeks for AL patients and 8 weeks for SCT patients). [clinicaltrials_resource:20d8c62cb48a99257eb1dc5e78e84d48]

The primary endpoint will be the safety defined by the incidence of adverse events occurring during the course of prophylaxis treatment (4 weeks for AL patients and 8 weeks for SCT patients). [clinicaltrials_resource:25f1be8ab4d032df37c080a7cd446378]

The primary endpoint will be the safety defined by the incidence of adverse events occurring during the course of prophylaxis treatment (4 weeks for AL patients and 8 weeks for SCT patients). [clinicaltrials_resource:49a14cfc66dfa9d0ccc7ce1abd285ca3]

The primary endpoint will be the safety defined by the incidence of adverse events occurring during the course of prophylaxis treatment (4 weeks for AL patients and 8 weeks for SCT patients). [clinicaltrials_resource:4e18b908234570f8345ee5512b4f6c21]

The primary endpoint will be the safety defined by the incidence of adverse events occurring during the course of prophylaxis treatment (4 weeks for AL patients and 8 weeks for SCT patients). [clinicaltrials_resource:53724e0195de3cf6678b069afce4f0a3]

The primary endpoint will be the safety defined by the incidence of adverse events occurring during the course of prophylaxis treatment (4 weeks for AL patients and 8 weeks for SCT patients). [clinicaltrials_resource:5628d3e2abc588f2792eed922237419d]

The primary endpoint will be the safety defined by the incidence of adverse events occurring during the course of prophylaxis treatment (4 weeks for AL patients and 8 weeks for SCT patients). [clinicaltrials_resource:75e8307619f5834f64fbd0821db61db2]

The primary endpoint will be the safety defined by the incidence of adverse events occurring during the course of prophylaxis treatment (4 weeks for AL patients and 8 weeks for SCT patients). [clinicaltrials_resource:76af5ae9babdb2b9771b0e28b24be6be]

The primary endpoint will be the safety defined by the incidence of adverse events occurring during the course of prophylaxis treatment (4 weeks for AL patients and 8 weeks for SCT patients). [clinicaltrials_resource:7716ff36f3a895e7d3f796d5697b8ea8]

completion date [clinicaltrials_vocabulary:completion-date]

2006-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

detailed description [clinicaltrials_vocabulary:detailed-description]

This pilot study was de ...... ons development is concerned.

http://www.w3.org/2001/XMLSchema#string

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00362544 [clinicaltrials_resource:fd6be130e55a733fd16610fa6fea7e92]

enrollment [clinicaltrials_vocabulary:enrollment]

30

http://www.w3.org/2001/XMLSchema#integer

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2006-05-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

No

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Ambisome [clinicaltrials_resource:10cc9be62c910e998c360d7315076c0f]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Amphotericin B [clinicaltrials_resource:4d8219fe88640c7896ac549d41adb320]

Liposomal amphotericin B [clinicaltrials_resource:7e5aca01920c37966c4c377e177a6fd8]

Antifungal Agents [clinicaltrials_resource:835965a3d5022b471688ab1ede3052ad]

Miconazole [clinicaltrials_resource:a5d5c86432f9365dc33a77988a426b00]

keyword [clinicaltrials_vocabulary:keyword]

acute leukaemia

http://www.w3.org/2001/XMLSchema#string

allogeneic stem-cell transplantation

http://www.w3.org/2001/XMLSchema#string

antifungal prophylaxis treatme ...... plantation and acute leukaemia

http://www.w3.org/2001/XMLSchema#string

antifungal prophylaxis

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2015-07-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Gilead Sciences [clinicaltrials_resource:ce52c7362053add2a60ae71cb7729d42]

location [clinicaltrials_vocabulary:location]

Gilead Sciences [clinicaltrials_resource:3fdcc303f23274994db5df465bf3b20f]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00362544

http://www.w3.org/2001/XMLSchema#string

official title [clinicaltrials_vocabulary:official-title]

Pilot Study on Safety of a Wee ...... plantation and Acute Leukaemia

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

GS-FR-131-104

http://www.w3.org/2001/XMLSchema#string

overall official [clinicaltrials_vocabulary:overall-official]

Lamine Mahi, MD [clinicaltrials_resource:5bcf2cdfbe6078dd1fc0bd0dbdc48815]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis) [clinicaltrials_resource:6c303086cccb1f7e617d6984dc161410]

phase [clinicaltrials_vocabulary:phase]

Phase 4 [clinicaltrials_resource:ec41833bc88cd90619c4d85c549688bd]

secondary id [clinicaltrials_vocabulary:secondary-id]

GS-FR-131-0119

http://www.w3.org/2001/XMLSchema#string

source [clinicaltrials_vocabulary:source]

Gilead Sciences [clinicaltrials_resource:ce52c7362053add2a60ae71cb7729d42]

start date [clinicaltrials_vocabulary:start-date]

2003-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00362544 study design [clinicaltrials_resource:ba1f5b79742ca86d6a677b25608eb0fa]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00362544

verification date [clinicaltrials_vocabulary:verification-date]

2015-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00362544

http://www.w3.org/2001/XMLSchema#string

title

PROPHYSOME: Pilot Study on Saf ...... plantation and Acute Leukaemia

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

PROPHYSOME: Pilot Study on Saf ...... a [clinicaltrials:NCT00362544]

@en